Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can add-on pioglitazone prevent recurrent stroke in patients with type 2 diabetes?

Nature Clinical Practice Neurology volume 3, pages 486–487 (2007)Cite this article

boxed-textWilcox R et al. (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38: 865–873

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dormandy JA et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289

    Article  CAS  Google Scholar 

  2. Nissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471

    Article  CAS  Google Scholar 

  3. Pfutzner A et al. (2006) Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev Cardiovasc Ther 4: 445–459

    Article  Google Scholar 

  4. Insulin Resistance Intervention after Stroke Trial [www.iristrial.org]

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Cleveland Clinic Foundation, S91, 9500 Euclid Avenue, Cleveland, OH 44195, USA katzani@ccf.org

Authors and Affiliations

  1. I Katzan is a Vascular Neurologist at Cleveland Clinic and Case Western Reserve University's Center for Health Care Research and Policy at MetroHealth Medical Center in Cleveland, OH, USA.,

    Irene Katzan

Authors
  1. Irene Katzan
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Katzan, I. Can add-on pioglitazone prevent recurrent stroke in patients with type 2 diabetes?. Nat Rev Neurol 3, 486–487 (2007). https://doi.org/10.1038/ncpneuro0562

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0562

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing